Royce & Associates Reduces Stake in Mesa Laboratories

Investment firm sells nearly 100,000 shares of medical instruments supplier

Mar. 4, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Royce & Associates LP, an investment management firm, has reduced its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 40% during the third quarter, according to a recent SEC filing. The firm sold 99,048 shares of the medical instruments supplier, leaving it with 148,558 shares, or approximately 2.7% ownership of the company.

Why it matters

This transaction highlights the shifting investment strategies of institutional investors and the fluctuations in ownership of publicly traded medical technology companies like Mesa Laboratories. The sale could signal a change in Royce & Associates' outlook on Mesa Laboratories or broader portfolio adjustments.

The details

According to the 13F filing, Royce & Associates sold 99,048 shares of Mesa Laboratories during the third quarter, reducing its total stake in the company by 40%. The investment firm now owns 148,558 shares, valued at approximately $9.96 million as of the most recent filing. Mesa Laboratories is a provider of instrumentation products for critical process monitoring, testing, and calibration across various industries including healthcare, pharmaceutical, and energy.

  • Royce & Associates reduced its stake in Mesa Laboratories during the third quarter of the year.

The players

Royce & Associates LP

An investment management firm that has reduced its stake in Mesa Laboratories, Inc.

Mesa Laboratories, Inc.

A provider of instrumentation products for critical process monitoring, testing, and calibration across various industries.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the dynamic nature of institutional investment strategies and the ongoing shifts in ownership of publicly traded medical technology companies. It will be important to monitor any further changes in Royce & Associates' position in Mesa Laboratories and how this may impact the company's operations and stock performance going forward.